3rd Quarter - Report

INNOVATIVE FEDERAL STRATEGIES, LLC for ADURO BIOTECH

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 5293 / S. 3000 Department of Defense Appropriations Act, 2017, Titles IV and VI, all provisions relating to cancer and infectious disease vaccines.

LobbyistCovered position, as disclosed
DAVID FREDERICK KILIAN —
CARL KIME —
KALI MATALON —
LETITIA WHITE —

Contacted: HOUSE OF REPRESENTATIVES; Vice President of the U.S.; SENATE

Bills named: H.R. 5293 (114th), S. 3000 (114th)

Government Issues GOV

Contacted White House Staff to Request a meeting on Moonshot Cancer Initiatives. Attended a meeting with an official from the office of the Vice President to discuss Aduro's cancer immunotherapies and possible collaboration with the Vice President's Cancer Task Force and Moonshot initiative. Contacted Members of Congress to provide the same information. Contacted Congressional offices on the status of the Cures Act. Contacted a Member of Congress regarding the ground breaking ceremony in California for Aduro's new facility.

LobbyistCovered position, as disclosed
DAVID FREDERICK KILIAN —
CARL KIME New —
KALI MATALON —
LETITIA WHITE —

Contacted: SENATE; Vice President of the U.S.; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.